Active, not recruitingPhase 1NCT03299309

PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

Studying Medulloblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Daniel Landi
Principal Investigator
Daniel Landi, MD
Duke University
Intervention
PEP-CMV(drug)
Enrollment
30 enrolled
Eligibility
3-35 years · All sexes
Timeline
2018 – 2026

Study locations (1)

Collaborators

Pediatric Brain Tumor Foundation · Annias Immunotherapeutics, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03299309 on ClinicalTrials.gov

Other trials for Medulloblastoma

Additional recruiting or active studies for the same condition.

See all trials for Medulloblastoma →

← Back to all trials